HG-6-64-1

HG-6-64-1 is a potent small molecule inhibitor of the Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase (RTK) that is frequently overexpressed in aggressive cancers and plays a significant role in tumor cell survival, proliferation, and metastasis. Developed by researchers at the Dana-Farber Cancer Institute and Massachusetts General Hospital, HG-6-64-1 was designed to target the oncogenic signaling pathways associated with EphA2. In preclinical studies, the compound has demonstrated the ability to inhibit the proliferation of NRAS and BRAF mutant melanoma cell lines. Furthermore, it suppresses cellular migration and invasion by disrupting actin cytoskeleton reorganization and lamellipodia formation. While primarily utilized as a chemical probe in academic research to study EphA2 biology, its activity in melanoma models suggests potential therapeutic utility, particularly as part of combination strategies with BRAF or MEK inhibitors.